Tonix Says Fibromyalgia Candidate Failed To Achieve Statistical Significance Over PlaceboBenzinga • 03/21/22
Tonix Pharmaceuticals Announces Phase 3 RALLY Study Results for TNX-102 SL 5.6 mg for the Management of FibromyalgiaGlobeNewsWire • 03/21/22
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Operational HighlightsGlobeNewsWire • 03/14/22
Tonix Pharmaceuticals Announces Appointment of Jeffrey Rosenfeld, Ph.D., as Executive Director, Genomics and BioinformaticsGlobeNewsWire • 03/09/22
Tonix Pharma Collaborates With Massachusetts General Hospital For TNX-1900 In Binge Eating DisorderBenzinga • 03/07/22
Tonix Pharmaceuticals Announces Collaboration with Massachusetts General Hospital to Evaluate TNX-1900 (Intranasal Potentiated Oxytocin) for Treating Binge Eating DisorderGlobeNewsWire • 03/07/22
Tonix Pharmaceuticals Announces FDA Orphan-Drug Designation for TNX-2900 for the Treatment of Prader-Willi SyndromeGlobeNewsWire • 03/03/22
Tonix Pharmaceuticals Announces Research Agreement with the French National Institute of Health and Medical Research (Inserm) to Study the Mechanism of Oxytocin-Mediated Improvement of Eating Behaviors in Prader-Willi MiceGlobeNewsWire • 02/28/22
Tonix Pharmaceuticals Initiates Enrollment in Clinical Trial of TNX-2100, a Diagnostic Skin Test to Measure Functional T Cell Immunity to SARS-CoV-2GlobeNewsWire • 01/11/22
Tonix Pharma, Kansas University Join Forces To Work On Next-Gen mRNA-Based COVID-19 VaccineBenzinga • 01/04/22
Tonix Pharmaceuticals Announces IND Clearance for Skin Test (TNX-2100) to Measure SARS-CoV-2 Exposure and T Cell ImmunityGlobeNewsWire • 12/14/21
Tonix Pharmaceuticals Announces Research Collaboration with Columbia University to Study Recombinant Trefoil Factor 2 (rTFF2)-Based Therapy (TNX-1700) for Gastric and Colorectal CancersGlobeNewsWire • 12/13/21